Bugworks raises $18M in Series B1 round
US, Australia, and Bengaluru-based Bugworks, a clinical-stage multi-indication therapeutics startup,announced that it has raised $18 million in Series B1 funding. The round was led by Lightrock India and included existing investors Bugworks is a clinical-stage biopharmaceutical company founded in February 2014 with the goal of developing novel anti-infectives and immuno-oncology (IO) therapeutic assets using cutting-edge … Read more